Seeing Is Believing
Currently out of the existing stock ratings of Danielle Brill, 151 are a BUY (80.75%), 31 are a HOLD (16.58%), 5 are a SELL (2.67%).
Analyst Danielle Brill, currently employed at RAYMOND JAMES, carries an average stock price target met ratio of 45.64% that have a potential upside of 28.99% achieved within 155 days.
Danielle Brill’s has documented 347 price targets and ratings displayed on 23 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on QURE, Uniqure NV at 10-Dec-2024.
Analyst best performing recommendations are on AGIO (AGIOS PHARM).
The best stock recommendation documented was for XLRN (ACCELERON PHARMA) at 1/8/2020. The price target of $73 was fulfilled within 20 days with a profit of $19.46 (36.35%) receiving and performance score of 18.17.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$28
$8.4 (42.86%)
$28
4 days ago
(27-Feb-2025)
25/37 (67.57%)
$8.66 (44.78%)
486
Buy
$27
$7.4 (37.76%)
$27
4 days ago
(27-Feb-2025)
7/21 (33.33%)
$7.66 (39.61%)
118
Buy
$28
$8.4 (42.86%)
$28
4 days ago
(27-Feb-2025)
0/6 (0%)
$8.66 (44.78%)
Hold
$22
$2.4 (12.24%)
$24
20 days ago
(11-Feb-2025)
16/21 (76.19%)
$3.51 (18.98%)
174
Hold
$20
$0.4 (2.04%)
$25
2 months ago
(03-Jan-2025)
5/6 (83.33%)
$1.59 (8.64%)
172
Which stock is Danielle Brill is most bullish on?
Which stock is Danielle Brill is most reserved on?
What Year was the first public recommendation made by Danielle Brill?